share_log

Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23

Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23

Oppenheimer公司开始对y-mabs therapeutics进行覆盖,给予跑赢大盘评级,宣布目标股价为23美元
Benzinga ·  2024/11/18 21:48  · 评级/大行评级

Oppenheimer analyst Jeff Jones initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform rating and announces Price Target of $23.

奥本海默分析师杰夫·琼斯对y-mabs therapeutics(纳斯达克:YMAB)开始覆盖,给予"跑赢大盘"评级,并宣布目标价为23美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发